The supervisory board of private joint-stock company Biofarma (Kyiv) on October 21, 2015 decided to close a company representative office in Belarus due to the restructuring of the company.

The company said that Biofarma fulfilled presentation functions in Belarus and was not involved in commercial operations.

As reported, on October 15, 2015, the supervisory board of Biofarma decided to close its representative office in Kazakhstan.

Biofarma is among the ten largest Ukrainian drug manufactures. Biofarma produces more than 20 immunobiological preparations of blood, as well as drugs obtained by recombinant DNA technology and probiotics.